British and American physicians have generally regarded asthma and COPD as distinct conditions with separate pathogenic factors and different clinical courses. However, the evidence in support ofthis model is by no means consistent.
The alternative model, known as the Dutch Hypothesis, regards asthma and COPD as two aspects of the same basic process, and there is some evidence in support of this model. In accepting this latter hypothesis it becomes apparent that genetic and environmental factors that determine the development of chronic inflammation, airflow obstruction, and the atopic phenotype in young asthmatics, might also be expected to have a role in the development of COPD and late onset asthma. Such a hypothesis need not exclude the importance of some nonasthma related factors in the development of COPD (such as alpha-1 -antitrypsin deficiency), and does not assume that the relative importance of factors is the same for the two conditions (e.g., smoking). However, it does provide an alternative basis on which to investigate the spectrum of airflow obstruction in older patients, in light of conflicting and incomplete evidence for the role of atopy, bronchial hyper-responsiveness, and pathological changes.
Firstly, in considering the nongenetic evidence, pathologically some distinction may be made between asthma and COPD, but there are also a number of similarities. The airways in asthma are characterized by increased numbers of CD4+ lymphocytes, eosinophils, and mast cells,4 with basement membrane thickening in nearly all cases.5 Induced sputum samples show a prominence of activated eosinophils. During acute exacerbations the small airways show increased muscle cell mass with mucus plugging.6'7 Chronic asthma is characterized by parenchymal and alveolar tissue inflammatory changes and eosinophil infiltrates.
By contrast the prominent cells in COPD are CD8+ lymphocytes, although CD4+ cells are also increased.
There is prominent neutrophil and macrophage infiltrate in induced sputum samples but sputum eosinophilia may be a feature in up to a third of cases, particularly during exacerbations. The small airways may show an increased muscle cell mass and mucus hypersecretion but there is also evidence of fibrosis and obliteration of the small airways. 8 Asthma in younger subjects is characterized by the presence of atopy, as demonstrated by elevated total and specific IgE levels, and positive skin tests to common aeroallergens. The importance of these factors to the A significant number of studies have not shown such a relationship between asthma and atopy in older persons.
The effect of smoking, which is known to elevate IgE levels, confounds the relationship between airflow obstruction and IgE in adults.'6'17 Patients with increased levels of total IgE, and eosinophilia are more likely to be subsequently diagnosed as having asthma rather than COPD, regardless of their smoking history and this potential for diagnostic inconsistency whilst it has not been shown to alter clinical management, may confound genetic studies. '8 Patients with asthma and COPD have variable responses to treatments, and disease progression also varies widely, both between asthma and COPD and within each condition. 3,17,19-21 What remains unclear is whether airflow obstruction is the result of a limited lung response to a range of stimuli, such as the Chronic Respiratory Disease environmental effects of tobacco, the effects of early childhood respiratory tract infection, extrinsic allergens, or inherited factors, or if asthma and COPD share pathogenic mechanisms that produce a variable response in the lung.
Cigarette smoking is the most important factor determining the development of COPD, but also to a lesser extent a risk factor for the development of asthma. Fletcher and Peto in 1977 suggested that only 10-15% of chronic heavy smokers would ever develop clinically significant airflow obstruction suggesting that other factors, both genetic and environmental are important.22'23 Amongst those smokers susceptible to the effects of tobacco smoke the disease severity and future prognosis appears to be correlated to total pack year history. However, Burrows et al. showed that total pack year history, current number of cigarettes smoked, average number of cigarettes smoked and age, only explained a small percentage (estimated at 15%) of the variability of height and sex adjusted FEV1 observed within the general population.24
Inheritance and obstructive lung disease
The possibility that hereditary factors may determine the individual susceptibility to obstructive lung disease 25 was initially proposed over 150 years ago.
A measure of the genetic contribution to a disease or phenotype that can be obtained from family and twin studies is heritability (H). This is defined as the phenotypic variance that may be attributed to genetic factors (often expressed as a percentage) and adjusted for the population prevalence of the trait. Frequently there is wide variation in the estimates given. Often this occurs due to a failure to control for significant environmental factors and difficulty in establishing if concordance is due to shared environment or shared genes. There is now considerable epidemiological and molecular evidence suggesting that FEV, clusters within families and is under a significant degree of genetic control.
FEV1 is an important component of both the asthma and COPD phenotype. By definition in COPD FEV, is less than 80% of its predicted value. 26 In asthma FEV, can fluctuate with time, typically falling during exacerbations. However chronic asthma in the elderly can be associated with a reduced FEVY 27 Givelber et al. (1998) , in a study of 5003 adults, showed significant sibling-sibling correlations and parental offspring correlations but trivial spousal correlations in FEV1.28 Identical patterns of corre- (1991) in a study involving 733 households. 31 It is possible that the genetic factors determining FEV, in a general population sample are quite distinct from those determining FEVy in families with COPD or asthma. However there is specific evidence regarding correlations in pulmonary function in families with a COPD index case. Although accurate estimates ofthe genetic heritability of COPD are difficult, the heritability of FEVy in these families may be as high as 77%. Twin-twin studies show that there is a closer similarity in spirometric function between monozygotic versus dizygotic twins and that in monozygotic twins who smoke there is a higher risk that both will develop airflow obstruction, even if raised apart, compared to dizygotic twins. There is evidence of familial clustering and an increased prevalence of COPD amongst relatives of patients with COPD compared to the relatives of controls and decreased prevalence of COPD with increased genetic distance. Larson et al. (1970) showed that abnormalities of pulmonary function were higher in 156 relatives of 61 subjects with COPD than their spousal controls. They suggested that genetic factors and smoking contributed equally to the likelihood of developing COPD. 32 Cohen et al. in a study of over 2500 individuals, showed that first degree relatives of patients with COPD had significantly higher rates of airflow obstruction compared with community based controls and first degree relatives of nonpulmonary patients. 33 Recently the same group found that within the COPD families there was significant evidence for a major gene effect (most probably many genes acting in unison rather than a single locus) contributing to pulmonary function, that was absent in nonpulmonary families. 34 There have been no studies examining the heritability of FEV, in families with a history ofchronic asthma, although there is considerable evidence that childhood asthma is also under a strong degree of genetic control. It is estimated to have a heritability of between 30 and 60%. Estimates of the heritability of total IgE are around 60%. In a study by Sibbald and Turner-Warwick (1992) it was suggested that the inheritance of atopic asthma was under greater genetic control than nonatopic asthma. 35 This group also suggested that asthma and atopy could be separately inherited and concluded that the manifestations of asthma may be enhanced in those with atopy. There has some attempt to discriminate between other asthmatic subtypes. For late onset disease it is unlikely that genetic factors are identical to those causing childhood atopic asthma, but there may still be a significant genetic overlap.
Insights from molecular genetic studies
The family studies suggest that asthma and COPD have a significant genetic component. Of the two conditions however it is asthma that has been the initial focus of genetic epidemiological studies. COPD is predominately a disease of late middle age and older people and as a consequence the determination of genetic factors is more complex for a number of reasons. 36 
Linkage studies
Linkage studies, which rely on the collection of genetic material from several generations of the same family, are rarely possible for a late onset condition such as COPD. Parents ofpatients with COPD are usually dead at the time disease presents and any children of cases are too young to have developed the disease and thus in genetic terms uninformative. Alternative approaches such as sibling pair studies can also be difficult due to geographical separation of siblings (in contrast to a study of young asthmatics where siblings will be living in the same household). Although difficult, linkage studies are important since they can provide useful information from which to direct a search for candidate genes. In a condition such as COPD where multiple candidate genes might be hypothesized they have a crucial role. The alternative approach to linkage based methods is the candidate gene study. This type of study is complementary to linkage based methods, but possible where linkage data is not available. Candidate gene association studies are not without their difficulties in older populations. In candidate gene approaches the selection ofrigorously matched controls is essential. Clearly, given the multiple environmental factors involved in the development of COPD, selection of an appropriate control group may be difficult.
There has been considerable progress in determining the genetic factors that contribute to the atopic and juvenile onset asthmatic phenotype. To date there have been six published whole genome linkage scans for asthma and atopy.37-42 Although they were carried out in distinct populations, and used some different diagnostic criteria for a number ofthe phenotypes, there were some areas oflinkage identified that were common to a number of studies. The 12q area (i.e., the long arm of chromosome 12) showed linkage in all studies and 5p (the short arm of chromosome 5), 1 lp, 13q, 6p and 7p areas were common to four studies. In addition there is considerable evidence for linkage for 11 q, 5q and to a lesser extent 16p from non genome linkage studies. The following regions have also been identified in linkage studies, 2q, 12p, 13q, 14q, 17p, 19q and 21q. The 19, 22, 17 , and 2q for a variety of COPD phenotypes. From this single study there is some but not much overlap with the linkage regions identified in the asthma linkage datasets. However the subjects were all awaiting surgery for emphysema and had disease onset before 53 years and FEVy of <40%, making them atypical of the general COPD population. Joost and colleagues examined quantitative markers of pulmonary function in a general population sample and reported linkage to chromosome 6q and 21p in their population.44 The relationship between genetic determinants of pulmonary function in the general population and those in COPD is unknown. The former may be of particular importance in lung growth and development rather than the development of COPD.
Candidate genes
There are a number of potential candidate genes for COPD summarized in Table 2 .
The tumour necrosis factor gene complex
The tumour necrosis factor gene complex lies on chromosome 6p in a region identified in four genome wide scans as linked to asthmatic phenotypes. Tumour necrosis factor (TNF) is a proinflammatory cytokine with varied roles in inflammatory processes. It is involved in the early phase of bronchoconstriction via smooth muscle contraction and the late phase via up regulation of adhesion molecules. A number of polymorphisms in and around the promoter region of the tumour necrosis factor gene have been described, one of which, the TNF-308 polymoThism, produces a functional increase in TNF levels. 5,46 An extended haplotype involving the adjacent lymphotoxin alpha gene has also been described. TNF alpha is released into the airways and serum of patients with asthma and children with active disease have increased serum TNF alpha levels.47 Although increased serum levels have not been found in patients with COPD, increased levels of TNF are found in the sputum of such patients.48 Furthermore where COPD is accompanied by weight loss there is increased release of TNF from circulating cells. 49 There have been a number of studies showing significant associations between the TNF gene complex and childhood asthma.50'51 The TNF-308 polymorphism has also been fairly extensively studied in subjects with COPD. Results have not been consistent, with some studies reporting a strong association between TNF polymorphisms associated with high levels of TNF secretion and COPD and others showing no such association. -56 Recently a Taiwanese group reported on an association between this polymorphism and self reported chronic bronchitis.52 However this study involved only small numbers of subjects and thus must be interpreted with caution. A second larger study, also of an Asian population, described statistically significant genetic association between the TNF-308 polymorphism and COPD.53 Two subsequent studies, both involving those of European origin, have failed to show any genetic association between the TNF polymorphisms and COPD, although they were also of limited size.54 '55 In a case-control study by Keating et al., an association was found between the rarer homozygotes variant at the TNF-308 locus and more severe disease with a poorer prognosis.56
The chromosome 5q 31-33 region has been linked to a range of asthmatic phenotypes in both genome wide screens and in nongenome wide genetic studies.38'39'57-60 There are a number of candidate genes for asthma and atopy within this region, (interleukin-13, interleukin-4, beta-2-adrenoceptor, interleukin-5, interleukin-3) and it is likely that all these loci contribute to the overall asthmatic phenotype. Some of the candidate genes within the region also have a very plausible role in the pathogenesis of COPD although, as has been mentioned, there remains a lack of linkage data to support the examination of a particular candidate gene.
The beta-2-adrenoreceptor
The beta-2-adrenoreceptor gene is one ofthe candidates within the region. 132 adrenoceptors (/2AR) are widely distributed in airway smooth muscle, particularly in the small airways, but also in other cells within the lung, such as mast cells and epithelial cells. Beta agonists interact with the receptor, probably by binding to and stabilizing the receptor in its activated form, thus producing airway smooth muscle relaxation and bronchodilation in patients with asthma.61'62 It is also possible that the beta agonists amplify a low inherent receptor activity to convert to the activated state. Furthermore there is some evidence to suggest that this shift may result in sustained changes that persist even in the absence of beta agonist.63 In addition the receptor undergoes desensitization, the extent of which is dependent on the degree and duration of the receptor/ agonist response. Given the known properties of the beta adrenoceptor one might predict that polymorphisms of the receptor would act as disease modifiers or alter responsiveness to beta agonist therapy.
A total of ninejpolymorphisms of the 132AR were initially identified, but only two which are likely to be functional are common in Caucasian populations, at codon 16 and at codon 27.
The polymorphisms have been shown to correlate with a number of asthmatic phenotypes although they do not seem to determine susceptibility to asthma, a finding confirmed in a recent meta-analysis of the linkage data. 65 A number of studies report differences in bronchidilator reversibility in young asthmatics, with the different polymorphic variants of the beta adrenoceptor gene.
Bronchodilator reversibility is increasingly recognized as a feature of COPD and the recent Lung Health Study found that over 60% of individuals had reversibility to bronchodilators at some stage.66 It is possible that bronchodilator reversibility in COPD may be similarly influenced by the beta adrenoceptor polymorphisms. This has yet to be examined in a genetic association study.
Other studies report that the polymorphisms have been associated with increased asthma severity defined on the basis of a need for hospital admission, higher maintenance dose of inhaled corticosteroids, nocturnal symptoms, or oral corticosteroid use.67-69 A number of these studies also included FEVy as one of their markers of severity. There have been two studies that report a direct association between the polymorphisms and pulmonary function, although their results are conflicting, and only one ofthe studies involved an adult population.68'70 A number of studies have not shown any significant associations with the beta adrenocpetor polymorphisms and disease.71 It is possible that the effects of the polymorphism on pulmonary function only become manifest with the natural decline in lung function that occurs with age (and is accelerated by smoking) and are confined to specific haplotypes rather than the independent action of closely linked polymorphisms.
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Interleukin-13
Interleukin-1 3 (IL-13) is another proinflammatory cytokine secreted from Th2 helper cells. IL-1 3 in mice mimics many ofthe features ofasthma including mucus hypersecretion and airways hyper-responsiveness. 74 Over expression of IL-13 in the murine lung also leads to the development of emphysema. 75 This raises the possibility that IL-13 polymorphisms associated with higher secretory levels may lead to the development of COPD/emphysema in smokers.
A number of polymorphisms of the IL-1 3 gene and promoter have been described. At least some of these are known to be functional causing altered regulation of IL-13 production. Previously, studies have shown one of the IL-13 promoter polymorphisms to be associated with allergic asthma and elevated total serum IgE levels.76 '77 To date there have been few studies examining the role of the polymorphisms in smokers with COPD and matched controls. One has shown a statistically significant genetic association between promoter polymorphisms of the IL-1 3 gene and COPD, although the other study was inconclusive.78'79 The final candidate to consider at the 5q3 1-33 locus is interleukin-4 (IL-4). IL-4 is critical for the synthesis of immunoglobulin E and eosinophil recruitment. It also promotes the differentiation of Th2 cells that underlies the asthmatic response.80 Children with atopic asthma have higher levels of IL-4. Numerous polymorphisms of the IL-4 gene and promoter have been described. At least some of these have been shown to be functional, resulting in altered IgE activity.
IL-4 levels are also significantly elevated in the plasma ofpatients with COPD suggesting that it may have a role in the pathogenesis of the airway inflammation and airflow obstruction observed in these patients.
Polymorphisms of the IL-4 gene have been linked and associated with a range of asthmatic phenotypes.81'82 Strong associations have been repeatedly demonstrated with physician diagnosed asthma and serum IgE levels in childhood atopic asthma.
The role of these polymorphisms in subjects with COPD has yet to be determined.
The Clara cell secretory protein
The Clara cell secretory protein (CC 16) gene lies in the 11 qI2-13 region, an area identified as strongly linked to asthmatic phenotypes in a number of studies. In murine models of asthma CC16 deficiency leads to excessive inflammatory responses within the airways. 83 Asthmatics demonstrate lower CC16 levels compared to matched controls and CC 16 expression is also decreased in the bronchial epithelium of COPD patients compared to smoking controls.84 '85 This suggests that CC 16 may have a pathogenic role in both conditions. Polymorphic variants of the CC 16 exist but have been less extensively studied than some of the other cytokines. A common polymorphism of the CC 1 6 gene is associated with decreased levels of CC 16 and in the same study low CC 16 levels were associated with asthma. 86 The same polymorphism has been associated with asthma severity in other studies, but the results have not been consistent. The role of CC 16 polymorphisms has not yet been examined in patients with COPD.
Conclusions
The genetic basis of asthma has yet to be clearly determined. The interplay of the multiple genetic and environmental factors involved is still far from clear and large population based studies are still on going. We know even less about the genetic factors that determine which smokers go on to develop COPD, although a few genetic mutations, such as alpha-1 -antitrypsin deficiency have a clear role in a minority of subjects.
COPD is a very diverse disease, and hence the combination of genetic factors that leads to the development of emphysema may be quite different from genetic factors leading to chronic bronchitis, or airflow obstruction in a smoker with preserved bronchodilator reversibility or steroid responsiveness. For practical purposes this means that genetic epidemiological studies need to focus on multiple sub phenotypes of COPD, or be powerful enough to allow for examination of different sub phenotypes.
At present it is not clear whether some of the asthma and atopy related genetic polymorphisms have a disease modifying or causative role in patients with COPD. The importance of pharmacogenetic factors in determining treatment in common disorders, particularly cancers, is already established. For example common polymorphisms of drug metabolizing enzymes and drug targets determine response to chemotherapeutic agents which explains the varied response of patients to a particular treatment. Within the field of cancer genetics such polymorphisms are already being used to optimize an individual's treatment. 87 The role of pharmacogenetic factors in the future management of asthma and COPD has yet to be determined.
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